Cargando…

Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells

Mesenchymal stem cells (MSCs) participate in the occurrence and development of multiple myeloma. This study is aimed at exploring whether the presence of MSCs affects dexamethasone's antitumor effects against multiple myeloma. Multiple myeloma cells (OPM-2 and RPMI8226 cells) were cocultured wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Mingyang, Yuan, Huan, Peng, Hongling, Liu, Sufang, Xiao, Xiang, Wang, Zhihua, Zhang, Guangsen, Xiao, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001108/ https://www.ncbi.nlm.nih.gov/pubmed/35419059 http://dx.doi.org/10.1155/2022/4855517

Ejemplares similares

Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3
por: Zhu, Shicong, et al.
Publicado: (2015)

Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorates Hippocampal Synaptic Impairment after Transient Global Ischemia
por: Deng, Mingyang, et al.
Publicado: (2017)

Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells
por: Guo, Wancheng, et al.
Publicado: (2021)

SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma
por: Du, Li, et al.
Publicado: (2022)

A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1(−) pre-B-ALL
por: Wang, Zhihua, et al.
Publicado: (2020)

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway
por: Atsuta, Ikiru, et al.
Publicado: (2013)

The role of Serpina3n in the reversal effect of ATRA on dexamethasone-inhibited osteogenic differentiation in mesenchymal stem cells
por: Jiang, Hai-Tao, et al.
Publicado: (2021)

The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis
por: Zhang, Yang, et al.
Publicado: (2021)

Proteomic profiling of plasma exosomes from patients with B-cell acute lymphoblastic leukemia
por: Zhu, Shicong, et al.
Publicado: (2022)

Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines
por: Friday, Ellen, et al.
Publicado: (2011)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma
por: Raimondo, Stefania, et al.
Publicado: (2020)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
por: Xu, Song, et al.
Publicado: (2018)

Deregulation of Mitochondrial ATPsyn-β in Acute Myeloid Leukemia Cells and with Increased Drug Resistance
por: Xiao, Xiang, et al.
Publicado: (2013)

Dexamethasone promotes mesenchymal stem cell apoptosis and inhibits osteogenesis by disrupting mitochondrial dynamics
por: Ma, Liang, et al.
Publicado: (2019)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis
por: Xiao, Juan, et al.
Publicado: (2015)

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
por: Kervoëlen, Charlotte, et al.
Publicado: (2015)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
por: Chim, C. S., et al.
Publicado: (2010)

Multiple myeloma cancer stem cells
por: Gao, Minjie, et al.
Publicado: (2016)

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
por: Hus, Marek, et al.
Publicado: (2011)

P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Nielsen, Lene Kongsgaard, et al.
Publicado: (2023)

An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells
por: Wang, Dan, et al.
Publicado: (2018)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression
por: García-Sánchez, Daniel, et al.
Publicado: (2023)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma
por: Iannozzi, Nicolas Thomas, et al.
Publicado: (2022)

Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells
por: Guo, Juan, et al.
Publicado: (2018)

Exploring the impact of dexamethasone on gene regulation in myeloma cells
por: Bessonneau-Gaborit, Victor, et al.
Publicado: (2023)

Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling
por: Wang, Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p7ajsv2uc38p93tn68695402d8